Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 Cash-to-Debt is 281.93 as of Mar. 2026, which is 90% above its 10-year median of 148.56. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.12 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 82.51% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Catalyst Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2026 was 281.93.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Catalyst Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Catalyst Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
CPRX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 33.21 Med: 148.56 Max: No Debt
Current: 281.93
During the past 13 years, Catalyst Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 33.21. And the median was 148.56.
CPRX's Cash-to-Debt is ranked better than 82.51% of 1395
companies
in the Biotechnology industry
Industry Median: 7.17
vs CPRX: 281.93
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Catalyst Pharmaceuticals Cash-to-Debt Related Terms
Catalyst Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (CPRX) has a Cash-to-Debt of 281.93 as of Mar. 2026. This is 90% above median its historical median of 148.56. Over the past decade, Catalyst Pharmaceuticals' Cash-to-Debt has ranged from 33.21 to 10,000.00. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #244 out of 1395 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Catalyst Pharmaceuticals' Cash-to-Debt too high?
Catalyst Pharmaceuticals' current Cash-to-Debt of 281.93 is 90% above median its 10-year median of 148.56. Over the past 10 years, this metric has ranged from a low of 33.21 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.17. Catalyst Pharmaceuticals' value of 281.93 is 3832.1% above this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #244 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Cash-to-Debt compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #244 out of 1395 companies for Cash-to-Debt. This places Catalyst Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.17. Catalyst Pharmaceuticals' value of 281.93 is 3832.1% above this benchmark. Historically, Catalyst Pharmaceuticals' own Cash-to-Debt has ranged from 33.21 to 10,000.00 over the past decade. While the company's 10-year median is 148.56 vs. the industry median of 7.17, Catalyst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current Cash-to-Debt of 281.93 is 3832.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current Cash-to-Debt is 281.93, which is 90% above median its own 10-year median of 148.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.12, compared to a current price of $31.49 — trading 25.4% above its estimated fair value. The current Cash-to-Debt is 281.93, which is 90% above median its 10-year median of 148.56 and 3832.1% above the Biotechnology industry median of 7.17. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Cash-to-Debt is 281.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.4% above its estimated GF Value™ of $25.12.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
Cash-to-Debt: 281.93 (90% above median its 10-year median of 148.56)
GF Value™: $25.12 vs. price of $31.49 (25.4% above fair value)
Industry Position: 3832.1% above the Biotechnology median (#244 of 1395)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
